摘要
目的探讨阿托伐他汀联合厄贝沙坦治疗糖尿病高血压病疗效及相关因素。方法选取2012年7月-2013年12月本院收治糖尿病高血压病患者100例,随机分为研究组及对照组各50例。观察治疗前及治疗后24周两组患者血糖及生化指标,血压,血肌酐（SCr）、血尿酸（UA）,微量白蛋白尿（MAU）及不良反应情况。结果研究组干预前后FPG、2h PG、Hb A1C、TG等指标比较,差异有统计学意义（P〈0.05）。治疗预后研究组的FPG、2h PG、Hb A1C、TG等指标显著低于对照组（P〈0.05）。治疗前、后收缩压与舒张压两组比较,差异不显著（P〉0.05）。治疗后研究组的血压下降水平明显高于对照组（P〈0.05）。两组治疗后MAU,血尿酸,糖化血红蛋白,肌酐及尿素氮水平显著低于对照组患者,两组比较差异有统计学意义（P〈0.05）。两组患者皆未见明显不良反应出现。结论血压、血糖、血脂等作为高血压病和糖尿病患者多重心血管危险因素,必须及时检测并采取相应治疗,以降低心血管病的发生率。
Objective To explore the related factors and therapeutic effect of statins combined with irbesartan in the treatment of diabetic hypertensive effects of atorvastatin. Methods 100 patients with essential hypertension From 2012 July to 2013 December in our hospital in patients withdiabetes and were randomly divided into study group and control group with 50 cases. 24 weeks of two groups of patients with blood glucose and biochemical indices were observed before treatment and after treatment of blood pressure,serum creatinine（SCr）,blood uric acid（UA）,microalbuminuria（MAU） and adverse circumstances were all observed. Results Comparison of FPG,2h PG,Hb A1 C,TG and other indexes before and after intervention research group,the difference was statistically significant（P〈0.05）. Give you a prognostic study groups FPG,2h PG,Hb A1 C,TG were significantly lower than those of the control group（P〈0.05）. Before and after the treatment,systolic and diastolic blood pressure of two groups,the difference was not significant（P〉0.05）. After treatment,the blood pressure decreased level in study group were significantly higher than the control group（P〈0.05）. The two groups after treatment MAU,glycosylated hemoglobin,blood uric acid,creatinineand urea nitrogen level was significantly lower than the patients in the control group,there was significant difference between two groups（P〈0.05）. The two groups were no obvious adverse reactions. Conclusion Blood pressure,blood glucose,blood lipids such as hypertension and diabetes mellitus patients with multiple cardiovascular risk factors,must be timely detection and appropriate treatment,to reduce the incidence ofcardiovascular diseases.
出处
《中国医药科学》
2014年第22期56-58,共3页
China Medicine And Pharmacy
